<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750334</url>
  </required_header>
  <id_info>
    <org_study_id>CLOMDS01206</org_study_id>
    <nct_id>NCT00750334</nct_id>
  </id_info>
  <brief_title>A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be used to determine the maximum tolerated dose of oral clofarabine when&#xD;
      administered daily for 14 consecutive days repeated every 21 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated to focus on comparable trial, CLOMDS02507&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated dose levels</measure>
    <time_frame>First Cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>After MTD is established</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect on profile</measure>
    <time_frame>After MTD is established</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of clofarabine in this dosing regimen</measure>
    <time_frame>Duration of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clofarabine Dose Escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
    <description>Drug given Daily x 14 days and 7 days of rest for 21 day cycle</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
    <description>Drug given Daily X 14 days and 7 days of rest for 21 day cycle</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed, written informed consent.&#xD;
&#xD;
          -  Be at least 18 years old.&#xD;
&#xD;
          -  Have a pathologically confirmed MDS and score according to the IPSS at study entry.&#xD;
             Pathologic confirmation is the responsibility of the investigator.&#xD;
&#xD;
          -  Have been treated previously for MDS as follow: a.Patients must have had at least 1,&#xD;
             but no more than 2, prior treatment regimens; b.Patients must not have refractory&#xD;
             (i.e., disease progression or no evidence of response while on treatment) to more than&#xD;
             1 prior treatment regimen.&#xD;
&#xD;
          -  Have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Be able to comply with study procedures and follow-up examinations.&#xD;
&#xD;
          -  Have adequate hepatic and renal function.&#xD;
&#xD;
          -  Be non-fertile or agree to use birth control during the study through the end of the&#xD;
             last treatment visit and at least 90 days after.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had a readjustment of dose and/or schedule of erythropoietin, granulocyte colony&#xD;
             stimulating factor(G-CSF) or other growth factors within 8 weeks prior to the first&#xD;
             dose of oral clofarabine.&#xD;
&#xD;
          -  Have had any other chemotherapy or any investigational therapy for MDS within 4 weeks&#xD;
             of the first dose of oral clofarabine.&#xD;
&#xD;
          -  Have not recovered to â‰¤ Grade 2 in severity of any drug-related non-hematologic&#xD;
             toxicity prior to the first dose of oral clofarabine.&#xD;
&#xD;
          -  Have an uncontrolled systemic fungal, bacterial, viral or other infection. Have a&#xD;
             history of serious disease involving the heart.&#xD;
&#xD;
          -  Have a clinically significant cardiac assessment at screening or a known family&#xD;
             history QT prolongation.&#xD;
&#xD;
          -  Currently uses a medication known to prolong the QT interval.&#xD;
&#xD;
          -  Have had any prior treatment with clofarabine (IV or oral).&#xD;
&#xD;
          -  Have had a diagnosis of another malignancy, unless the patient has been disease free&#xD;
             for at least 3 years after completing curative intent therapy except for the&#xD;
             following: a. Patients with treated non-melanoma skin cancer, in situ carcinoma, or&#xD;
             cervical intraepithelial neoplasia, regardless of the disease-free duration, are&#xD;
             eligible for this study if definitive treatment or the condition has been completed.&#xD;
             b. Patients with organ-confined prostate cancer with no evidence of recurrent or&#xD;
             progressive disease based on prostate specific antigen (PSA) values are also eligible&#xD;
             for this study if hormonal therapy has been initiated or a radical prostatectomy has&#xD;
             been performed.&#xD;
&#xD;
          -  Have prior positive test for the human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Have gastrointestinal disease or prior surgery, which may affect the ability of the&#xD;
             patient to absorb oral clofarabine.&#xD;
&#xD;
          -  Is currently participating in another concurrent investigational protocol that is not&#xD;
             restricted to data and/or sample collection for patient demographic and/or disease&#xD;
             purposes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malignant Hematology Administration, H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>September 9, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Clofarabine,</keyword>
  <keyword>relapsed/refractory MDS,</keyword>
  <keyword>Myelodysplastic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

